secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001193805-23-001486
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic reports Q3 2023 net loss $22.8M; positive CALLIPER interim NfL data
---------------------------------------------------------------------------

- Net loss of $22.8M ($0.51/sh) for Q3 2023 vs $21.2M ($0.69/sh) in Q3 2022.
- Cash and investments of $59.7M as of Sep 30, 2023; expected runway into Sep 2024.
- Phase 2 CALLIPER trial in progressive MS met interim biomarker endpoint: serum NfL improved vs placebo across all subtypes.
- Received US patent notice of allowance for vidofludimus calcium in relapsing MS, extending protection to 2041.
- CALLIPER enrollment completed (467 pts); top-line data expected April 2025; ENSURE interim futility late 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380523001486/0001193805-23-001486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380523001486/e619056_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-23-001486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer